Individual Article: Clascoterone Cream 1%: Mechanism of Action, Efficacy, and Safety of a Novel, First-in-Class Topical Antiandrogen Therapy for Acne

June 2023 | Volume 22 | Issue 6 | SF350992s7 | Copyright © June 2023


Published online May 31, 2023

Hannah Peterson BSa, Leon Kircik MDb,c, April W. Armstrong MD MPHd

aLoma Linda University School of Medicine, Loma Linda, CA
bIcahn School of Medicine at Mount Sinai, New York, NY; Indiana University Medical Center, Indianapolis, IN;
Physicians Skin Care, PLLC Louisville, KY; DermResearch, PLLC Louisville, KY; Skin Sciences, PLLC Louisville, KY
cIndiana University Medical Center, Indianapolis, IN
dDepartment of Dermatology, Keck School of Medicine of University of Southern California, Los Angeles, CA

DISCLOSURES

April W Armstrong MD MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira,  Sanofi, Regeneron, and Pfizer.

Hannah Peterson BS has no conflicts of interest to disclose. 

Leon Kircik MD has served as either a speaker, consultant, advisor or an investigator for Allergan, Abbvie, Bausch Health, Cipher Canada, Galderma, GSK, J&J, Novartis, Ortho Dermatologics, Pfizer, Promius, Primus, Sun Pharma, Taro.

REFERENCES

  1. Fox L, Csongradi C, Aucamp M, et al. Treatment modalities for acne. Molecules. 2016;21(8). doi:10.3390/molecules21081063. 
  2. Habeshian KA, Cohen BA. Current issues in the treatment of acne vulgaris. Pediatrics. 20222020;145(Suppl 2):S225-S230. doi:10.1542/ peds.2019-2056L.
  3. Alkhodaidi ST, Al Hawsawi KA, Alkhudaidi IT, et al. Efficacy and safety of topical clascoterone cream for treatment of acne vulgaris: a systematic review and meta-analysis of randomized placebo-controlled trials. Dermatol Ther. 2021;34(1):e14609. doi:10.1111/dth.14609.
  4. Leung AK, Barankin B, Lam JM, et al. Dermatology: how to manage acne vulgaris. Drugs Context. 2021;10:2021-8-6. doi: 10.7573/dic.2021-8-6.
  5. Eichenfield L, Hebert A, Gold LS, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;83(2):477- 485. doi:10.1016/j.jaad.2020.04.087.
  6. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621-630. doi:10.1001/jamadermatol.2020.0465.
  7. Adler BL, Kornmehl H, Armstrong AW. Antibiotic resistance in acne treatment. JAMA Dermatol. 2017;153(8):810-811. doi: 10.1001/ jamadermatol.2017.1297.
  8. Dhillon S. Clascoterone: First approval. Drugs. 2020;80(16): 1745-1750. doi:10.1007/s40265-020-01417-6.
  9. Kircik LH. Game changer in acne treatment. J Drugs Dermatol. 2020;19(3):28.
  10. Sanchez C, Keri J. Androgen receptor inhibitors in the treatment of acne vulgaris: efficacy and safety profiles of clascoterone 1% cream. Clin Cosmet Investig Dermatol. 2022;15:1357-1366. doi: 10.2147/CCID. S289750.
  11. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73 e33. doi: 10.1016/j.jaad.2015.12.037.
  12. Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412-418. 
  13. WINLEVI (clascoterone) cream, Full Prescribing Information. Federal Drug Administration. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2020/213433s000lbl.pdf. Accessed December 3, 2022.
  14. Drake L, Reyes-Hadsall S, Barbieri JS, et al. New developments in topical acne therapy. Am J Clin Dermatol. 2022;23(2):125-136. doi:10.1007/ s40257-021-00666-9.
  15. Burma N, Woo T, Parsons L. Topical clascoterone for acne vulgaris. Skin Ther Lett. 2022-02-01 2022;27(1):1-3.
  16. Kim ES, Keam SJ. Clascoterone 1% cream in acne vulgaris: a profile of its use. Drugs & Therapy Perspectives. 2021;37(5):194-198. doi: 10.1007/ s40267-021-00831-4.
  17. Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung. 2004;54(12):881-886. doi:10.1055/s-0031-1297043.
  18. Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177-83. doi: 10.1111/j.1365-2133.2011.10332.x.
  19. Mazzetti A, Moro L, Gerloni M, et al. A phase 2b, randomized, doubleblind vehicle controlled, dose escalation study evaluating clascoterone 0.1%, 0.5%, and 1% topical cream in subjects with facial acne. J Drugs Dermatol. 2019;18(6):570.
  20. Han JJ, Faletsky A, Barbieri JS, et al. New acne therapies and updates on use of spironolactone and isotretinoin: a narrative review. Dermatol Ther (Heidelb). 2021;11(1):79-91. doi:10.1007/s13555-020-00481-w.
  21. Harris C. Clascoterone (Winlevi) for the treatment of acne. Am Fam Physician. 2021;104(1):93-94.
  22. Mazzetti A, Moro L, Gerloni M, et al. pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, cb-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.
  23. Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241-8. doi: 10.2147/CCID.S114830
  24. Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the novel androgen receptor inhibitor fits into the acne treatment paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi: 10.1177/1060028021992055.
  25. Piszczatoski CR, Powell J. Topical clascoterone: the first novel agent for acne vulgaris in 40 years. Clin Ther. 2021;43(10):1638-1644.
  26. UpToDate. Acne vulgaris: overview of management. Available at: https://www.uptodate.com/contents/acne-vulgaris-overview-ofmanagement? search=clascoterone&source=searchresult&selectedTitle= 1~5&usage_type=default&display_rank=. Accessed December 29, 2022.

AUTHOR CORRESPONDENCE

April W. Armstrong MD MPH armstrongpublication@gmail.com
Close Menu